Trial Profile
A Phase III, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as Reference
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Corifollitropin alfa (Primary) ; Follitropin beta
- Indications Female infertility
- Focus Registrational; Therapeutic Use
- Acronyms ENGAGE
- Sponsors Merck & Co; Organon
- 19 Oct 2011 Results comparing efficacy outcomes in North America versus European Union presented at the 67th Annual Meeting of the American Society for Reproductive Medicine.
- 28 Jan 2010 Results presented in a Merck & Co media release.
- 28 Jan 2010 Updated actual patient numbers from 1509 to 1506 according to a Merck & Co media release.